Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11152833 | 0.85 | ALOX15 (0.60) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| SCHEMBL29941729 | 0.84 | LMNA (0.82) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| SCHEMBL2328960 | 0.84 | LMNA (0.82) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| SCHEMBL11096263 | 0.84 | LMNA (0.47) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| SCHEMBL1496733 | 0.82 | LMNA (0.68) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| SCHEMBL11104803 | 0.81 | KDM4E (0.66) | LMNACYP1A2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10386574 | 0.80 | LMNA (0.45) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| Guaifenesin SCHEMBL4322 | 0.79 | CYP1A2 (1.00) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| Guaifenesin SCHEMBL4321 | 0.79 | CYP1A2 (1.00) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E | |
| SCHEMBL14112094 | 0.79 | LMNA (0.74) | LMNACYP1A2AGTR1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4379788-A | HYPOTENSIVES, ANTIARRHYTHMIA, B-BLOCKERS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-04-12 | — | — | US | claimed |
| US-4349549-A | Anti-hypertensive 1-substituted spiro(piperidine-oxobenzoxazine)s | SYNTEX (U.S.A.) INC. (US) | 1982-09-14 | — | — | US | claimed |
| CN-105963676-A | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| US-8664379-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| CN-103130684-A | Polymorphism of methocarbamol dipotassium phosphate and preparation method thereof | UNIV NANKAI | 2013-06-05 | — | — | CN | disclosed |
| CN-103130683-A | Polymorphism of methocarbamol dihydric phosphate and preparation method thereof | UNIV NANKAI | 2013-06-05 | — | — | CN | disclosed |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2010074807-A1 | 3, 4-DIHYDROQUINOLIN-2 ( 1H ) -ONE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-0303227-B1 | ETHERS AND THIOETHERS HAVING THERAPEUTICAL ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1992-02-05 | — | — | EP | disclosed |
| US-4968706-A | MUCOLYTIC, ANTITUSSIVE, BRONCHODILATOR, ANTIINFLAMMATORY | BOEHRINGER MANNHEIN ITALIA, S.P.A. (IT) | 1990-11-06 | — | — | US | disclosed |
| US-4379788-A | HYPOTENSIVES, ANTIARRHYTHMIA, B-BLOCKERS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNH3 | LMNA 2206/4885CYP1A2 2073/4885AGTR1 152/4885 |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | LMNA 2017/4885CYP1A2 1928/4885AGTR1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.